SECAUCUS, N.J. and COLUMBIA, Mo., Feb. 11, 2019 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that it has completed its previously announced acquisition of the clinical laboratory services business of Boyce & Bynum Pathology Laboratories (BBPL), a leading provider of diagnostic and clinical laboratory services in the Midwest.
Through a separate professional services agreement, Boyce and Bynum Pathology Professional Services, Inc. (BBPPS), is now the exclusive pathology provider for Quest Diagnostics clients in Missouri and a preferred pathology provider in the greater Midwestern region. Additional financial terms were not disclosed.
The aim for the transaction is to bring a broader menu of innovative clinical laboratory and pathology services to patients and providers throughout the region. In addition, the relationship will provide patients with access to an expanded network of service centers across the Midwest, for greater convenience.
About Quest Diagnostics
Quest Diagnostics empowers people to take action to improve health outcomes. Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management. Quest annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our 45,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives. www.QuestDiagnostics.com
SOURCE Quest Diagnostics